We are applying our TransCon technology to build a fully integrated, rare disease-focused biopharmaceutical company with a diversified pipeline of long-acting prodrug therapies that address unmet needs.
1Based on market data and Company estimates
2Includes all indications
3Based on treatment of ~25% of the U.S. patient population of ~80,000 patients